StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research note released on Sunday. The brokerage issued a hold rating on the biopharmaceutical company's stock.
Acorda Therapeutics Price Performance
ACOR stock opened at $0.31 on Friday. Acorda Therapeutics has a 1 year low of $0.28 and a 1 year high of $4.99. The company has a market cap of $7.53 million, a P/E ratio of -0.03 and a beta of 0.45. The firm has a 50-day moving average of $0.43 and a 200 day moving average of $0.83. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.86 and a quick ratio of 1.49.
Get
Acorda Therapeutics alerts:
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The company had revenue of $31.05 million during the quarter.
Hedge Funds Weigh In On Acorda Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in ACOR. Renaissance Technologies LLC increased its stake in shares of Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after purchasing an additional 194,100 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Acorda Therapeutics during the second quarter valued at approximately $68,000. Millennium Management LLC increased its stake in shares of Acorda Therapeutics by 661.2% during the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock valued at $145,000 after purchasing an additional 270,588 shares in the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of Acorda Therapeutics during the second quarter valued at approximately $28,000. Institutional investors own 50.24% of the company's stock.
About Acorda Therapeutics
(Get Rating)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research note released on Sunday. The brokerage issued a hold rating on the biopharmaceutical company's stock.
斯托克新闻网在周日发布的一份研究报告中对阿科达治疗公司(纳斯达克：ACOR-GET评级)的股票进行了报道。该经纪公司对这家生物制药公司的股票发布了持有评级。
Acorda Therapeutics Price Performance
ACOR stock opened at $0.31 on Friday. Acorda Therapeutics has a 1 year low of $0.28 and a 1 year high of $4.99. The company has a market cap of $7.53 million, a P/E ratio of -0.03 and a beta of 0.45. The firm has a 50-day moving average of $0.43 and a 200 day moving average of $0.83. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.86 and a quick ratio of 1.49.
雅高股价上周五开盘报0.31美元。Acorda Treeutics的一年低点为0.28美元，一年高位为4.99美元。该公司市值为753万美元，市盈率为-0.03，贝塔系数为0.45。该公司的50日移动均线切入位在0.43美元，200日移动均线切入位在0.83美元。该公司的债务权益比为2.10，流动比率为1.86，速动比率为1.49。
Get
Acorda Therapeutics
alerts:
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The company had revenue of $31.05 million during the quarter.
阿科达治疗公司(纳斯达克：ACOR-GET评级)最近一次发布季度收益报告是在8月4日星期四。这家生物制药公司公布的季度每股收益(EPS)为2.78美元，低于分析师普遍预期的0.36美元和2.42美元。阿科达治疗公司的净资产回报率为负90.29%，净利润率为负98.25%。该公司本季度的收入为3105万美元。
Hedge Funds Weigh In On Acorda Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in ACOR. Renaissance Technologies LLC increased its stake in shares of Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after purchasing an additional 194,100 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Acorda Therapeutics during the second quarter valued at approximately $68,000. Millennium Management LLC increased its stake in shares of Acorda Therapeutics by 661.2% during the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock valued at $145,000 after purchasing an additional 270,588 shares in the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of Acorda Therapeutics during the second quarter valued at approximately $28,000. Institutional investors own 50.24% of the company's stock.
一些机构投资者和对冲基金最近改变了他们在ACOR的头寸。复兴科技有限责任公司在第二季度增持了Acorda治疗公司的股份27.4%。复兴科技有限责任公司现在持有这家生物制药公司901,318股股票，价值42万美元，上个季度又购买了194,100股。Virtu Financial LLC在第二季度购买了Acorda治疗公司新的股票头寸，价值约6.8万美元。千禧管理公司在第二季度增持了661.2%的阿科达治疗公司的股份。Millennium Management LLC现在持有这家生物制药公司311,509股股票，价值145,000美元，上个季度又购买了270,588股。最后，保诚金融公司在第二季度购买了新的Acorda Treateutics股票，价值约28,000美元。机构投资者持有该公司50.24%的股票。
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Acorda治疗公司是一家生物制药公司，在美国开发和销售神经疾病的治疗方法。该公司在欧洲营销Ampyra(达法普利定)，一种改善多发性硬化症(MS)患者行走能力的口服药物；以及Inbrija，用于治疗帕金森病的间歇期。
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 免费获取StockNews.com关于Acorda治疗公司(ACOR)的研究报告
- 对塔吉特来说，最糟糕的时期可能已经过去，但这只股票买起来安全吗？
- 这些液态天然气股票准备好上行了吗？
- 内部人士正在买入的两只有趣的股票
- 诺华在避险市场中仍是一只冒险的股票
- 连续60年提高股息的3只防御性股票
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Acorda治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acorda Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
